Contact
Investor Relations
Overview
News
Research & Development
Overview
Current Collaborations
Clinical Studies
siRNA
Intellectual Property
Product Candidates
Development Pipeline
PF-655
QPI-1002
QPI-1007
Program for Pipeline siRNAs
Disease Indications
About Us
Company Profile
Letter from the CEO
Management
Board of Directors
Mission, Vision and Values
Licensing Partners
News
Careers
Website Disclaimer
Product Candidates
Development Pipeline
PF-655
QPI-1002
QPI-1007
Program for Pipeline siRNAs
Disease Indications
Last News
More News >
4.1.12
Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007
5.3.11
Rutgers Offers Hope in New Treatment for Spinal Cord Injuries
18.3.11
In a Phase 2 Study PF-04523655 (RTP801I-14) Showed Improved Vision Over Standard of Care in Patients with Diabetic Macular Edema at 12 Months
15.7.10
Nitto Denko and Quark Pharmaceuticals to Enter into Collaboration to Develop a Novel siRNA Anti-fibrotic Drug
28.6.10
Quark Pharmaceutical’s QPI-1007 Exhibits Neuroprotective Effects in Glaucoma Model
Development Pipeline
PF-655 (RTP801i14)
Partner:
Pfizer
Disease:
Diabetic Macular Edema
Disease:
Wet Age-related Macular Degeneration
QPI 1002(I5NP)
Partner:
Option granted to Novartis
Disease:
Acute Kidney Injury (AKI)
Disease:
Kidney Transplantation (DGF)
QPI 1007
Disease:
Non-arteritic Anterior Ischemic Optic Neuropathy
Disease:
Glaucoma
Programs for Pipeline siRNAs in several diseases